芦可替尼用于慢性淋巴细胞白血病患者症状控制:单组2期试验
这项单组2期试验在2014年9月15日至2015年9月20日期间纳入41例不需要全身治疗的慢性淋巴细胞白血病(CLL)患者,给予芦可替尼10 mg口服每日两次。治疗3个月时,简明疲劳量表(BFI)评分较基线平均变化百分比为44.3%(SD 35.0,p<0.0001),症状干扰评分平均变化百分比为43.4%(SD 51.5,p<0.0001),MD Anderson症状量表(MDASI)评分平均变化百分比为42.1%(SD 37.4,p<0.0001)。作者认为芦可替尼与疾病相关症状的显著改善相关,需要进一步研究测试其在CLL中的治疗疗效。
要点
- 41例不需要全身治疗的CLL患者接受芦可替尼10 mg口服每日两次。
- 3个月时BFI评分较基线平均变化百分比为44.3%(SD 35.0,p<0.0001)。
- 32例(78%)患者BFI平均评分降低20%或以上,24例(59%)过去24小时最严重疲劳评分降低2个单位或以上。
核心结论
- 在CLL患者中,芦可替尼与疾病相关症状的显著改善相关,以BFI、MDASI和症状干扰评分衡量。
- 需要进一步研究测试芦可替尼在CLL中的治疗疗效。
研究设计与样本
- 单组2期试验,在MD Anderson癌症中心(美国德克萨斯州休斯顿)于2014年9月15日至2015年9月20日期间入组不需要全身治疗的症状性CLL患者。
- 参与者接受芦可替尼10 mg口服每日两次。
- 在治疗前和治疗3个月后评估简明疲劳量表(BFI)、MD Anderson症状量表(MDASI)CLL模块及症状相关日常活动干扰评分。
- 共入组41例患者(25例既往未接受CLL治疗,16例既往接受过治疗)。
主要发现
- 3个月时,BFI评分较基线平均变化百分比为44.3%(SD 35.0,p<0.0001)。
- 3个月时,症状干扰评分较基线平均变化百分比为43.4%(SD 51.5,p<0.0001)。
- 3个月时,MDASI评分较基线平均变化百分比为42.1%(SD 37.4,p<0.0001)。
- 32例(78%)患者BFI平均评分降低20%或以上,24例(59%)患者BFI评估的过去24小时最严重疲劳评分降低2个单位或以上。
- 最常见的3-4级不良事件为中性粒细胞减少(n=2 [5%])、高血压(n=2 [5%])、失眠(n=1 [2%])、耳鸣和头晕(n=1 [2%])以及血小板减少(n=1 [2%])。
局限性
- 需要进一步研究测试芦可替尼在CLL中的治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease-related symptoms impair the quality of life of patients with chronic lymphocytic leukaemia (CLL) who do not require systemic therapy. Available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients with myelofibrosis, we postulated that ruxolitinib would improve disease-related symptoms in patients with CLL. We did a phase 2 trial of ruxolitinib to test this hypothesis. METHODS: Symptomatic patients with CLL who did not require systemic therapy were enrolled at MD Anderson Cancer Center (Houston, TX, USA) between Sept 15, 2014, and Sept 20, 2015. Participants were given 10 mg ruxolitinib orally twice a day. Scores on the Brief Fatigue Inventory (BFI), CLL module of the MD Anderson Symptom Inventory (MDASI) and symptom-associated interference in daily activities, were assessed before treatment and after 3 months. This trial is ongoing and is registered at ClinicalTrials.gov (NCT02131584). FINDINGS: 41 patients (25 previously untreated for CLL and 16 previously treated) were enrolled. At 3 months, the mean percentage change from baseline in BFI score was 44·3% (SD 35·0, p<0·0001), in symptom interference score was 43·4% (51·5, p<0·0001), and in MDASI score was 42·1% (37·4, p<0·0001). 32 (78%) of the patients experienced 20% or greater reduction in the mean BFI, and 24 (59%) had a reduction of two units or more in worst fatigue score in past 24 hours as assessed by the BFI. The most comment grade 3-4 adverse events were neutropenia (n=2 [5%]), hypertension (n=2 [5%]), insomnia (n=1 [2%]), tinnitus and dizziness (n=1 [2%]), and thrombocytopenia (n=1 [2%]). INTERPRETATION: In patients with CLL, ruxolitinib was associated with significant improvements in disease-related symptoms as measured by BFI, MDASI, and symptom interference scores. Further studies to test the therapeutic efficacy of ruxolitinib in CLL are warranted. FUNDING: Incyte, National Cancer Institute.
引用
- Jain P, Keating M, Renner S, et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017. PMID: 28089238. doi:10.1016/S2352-3026(16)30194-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。